TRAJ54: A Key Regulator of T Cell Activation and Inflammation

Target Name: TRAJ54

NCBI ID: G28701

TRAJ54

Other Name(s): T cell receptor alpha joining 54

TRAJ54: A Key Regulator of T Cell Activation and Inflammation

T cell receptor alpha joining 54 (TRAJ54) is a protein that plays a crucial role in the immune system. It is a type of protein known as a co-receptor, which means it is found in the same family of proteins as the T cell receptor alpha (TCR-伪), which is the protein that allows T cells to recognize and respond to foreign antigens.

TRAJ54 is a 190- amino acid protein that is expressed in many different tissues and cells in the body, including the spleen, lymph nodes, and various types of epithelial cells. It is a key regulator of the immune response and has been shown to play a role in a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

One of the key functions of TRAJ54 is its role in regulating the activation and proliferation of T cells. T cells are a type of white blood cell that play a critical role in the immune system by helping to detect and respond to foreign antigens. When an antigen binds to the TCR-伪 protein on the surface of a T cell, it triggers a signaling cascade that activates the T cell and begins to divide and differentiate into a T-cell.

TRAJ54 is involved in this process by helping to regulate the level of phosphorylation on the TCR-伪 protein. Phosphorylation is the process by which proteins are modified with a phosphate group, which can activate various downstream signaling pathways. In the case of T cells, the TCR-伪 protein is phosphorylated on its extracellular domain, which is the part of the protein that interacts with the antigens.

TRAJ54 has been shown to play a role in regulating the level of phosphorylation on the TCR-伪 protein in T cells. Studies have shown that TRAJ54 can inhibit the phosphorylation of the TCR-伪 protein at itsextracellular domain, which can reduce the level of activation and proliferation of T cells.

In addition to its role in regulating T cell activation and proliferation, TRAJ54 is also involved in the regulation of inflammation. T cells are a key source of immune inflammation, and their activation and proliferation can contribute to the development and progression of a variety of inflammatory diseases.

TRAJ54 has been shown to play a role in the regulation of inflammation by helping to control the production of pro-inflammatory cytokines. Pro-inflammatory cytokines are a type of molecule that play a key role in the immune response by promoting the recruitment and activation of immune cells, including T cells.

Studies have shown that TRAJ54 can inhibit the production of pro-inflammatory cytokines by regulating the activity of various enzymes involved in the synthesis and degradation of these molecules. This can help to prevent the production of pro-inflammatory cytokines and reduce the level of inflammation in the body.

In conclusion, T cell receptor alpha joining 54 (TRAJ54) is a protein that plays a critical role in the immune system. It is involved in regulating the activation and proliferation of T cells, as well as the regulation of inflammation. Given its involvement in these critical processes, TRAJ54 has potential as a drug target or biomarker for a variety of immune-related diseases. Further research is needed to fully understand the role of TRAJ54 in the immune system and to develop effective treatments for these diseases.

Protein Name: T Cell Receptor Alpha Joining 54

The "TRAJ54 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ54 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets